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CMG2/ANTXR2 regulates extracellular collagen
VI which accumulates in hyaline ﬁbromatosis
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Loss-of-function mutations in capillary morphogenesis gene 2 (CMG2/ANTXR2),
a transmembrane surface protein, cause hyaline ﬁbromatosis syndrome (HFS), a severe
genetic disorder that is characterized by large subcutaneous nodules, gingival hypertrophy
and severe painful joint contracture. Here we show that CMG2 is an important regulator of
collagen VI homoeostasis. CMG2 loss of function promotes accumulation of collagen VI in
patients, leading in particular to nodule formation. Similarly, collagen VI accumulates
massively in uteri of Antxr2 / mice, which do not display changes in collagen
gene expression, and leads to progressive ﬁbrosis and sterility. Crossing Antxr2 / with
Col6a1 / mice leads to restoration of uterine structure and reversion of female infertility.
We also demonstrate that CMG2 may act as a signalling receptor for collagen VI and
mediates its intracellular degradation.
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H
yaline ﬁbromatosis syndrome (HFS) is a painful and
disﬁguring, potentially lethal, genetic disorder, the hall-
mark of which is the progressive growth of subcutaneous
nodules, caused by accumulation of extracellular matrix (ECM).
Patients also present gingival hypertrophy, severe and painful
joint contracture, skin thickening and hyperpigmentation over
the large joints1,2. HFS is caused by loss-of-function mutations in
capillary morphogenesis gene 2 (refs 3,4) (CMG2), also known as
anthrax toxin receptor 2 (ANTXR2). The ANTXR2/CMG2 gene
encodes a single-pass transmembrane protein harbouring an
extracellular von Willebrand A (vWA) domain proposed to bind
collagen IV and laminin5. The ANTXR2 name stems from its
well-characterized role in binding and endocytosis of Bacillus
anthracis toxins6,7. However, its physiological role is poorly
understood. In zebraﬁsh, it is involved in orienting cell division
during embryogenesis within the planar cell polarity pathway8.
In mice, Antxr2 knockout was ﬁrst reported to have no
major consequence, other than resistance to anthrax infection9.
Subsequent observations however showed that female Antxr2 /
mice suffer from severe progressive ﬁbrosis of the uterus leading
to disruption of tissue architecture and failure of parturition10,11.
Here we discovered an uncharacterized function of CMG2 that
can account for both the presence of nodules in HFS patients and
the uterine phenotype in mice. We show that both the nodules of
HFS patient and the uteri of Antxr2 / female mouse are highly
enriched in collagen VI. The progressive accumulation of collagen
VI leads to loss of uterus integrity and ultimately sterility.
Remarkably, we ﬁnd that Antxr2 / ::Col6a1 / double
knockout mice are fertile, with complete restoration of the
uterine myometrial layers. We go on to show that CMG2 may be
a receptor for collagen VI and mediates its transport to lysosomes
for degradation. Thus, loss of CMG2 function causes accumula-
tion of collagen VI in the ECM, which with time may lead to
tissue disruption and disease. The identiﬁcation of CMG2 as
collagen VI regulator opens new avenues towards understanding
other processes involving this ECM protein such as obesity-
induced insulin resistance12,13 and muscle homoeostasis14.
Results
Accumulation of collagen VI in HFS patient nodules. Two
biopsies of nodules, which often form at body site exposed to
mechanical stress15, were obtained from a 6-year-old HFS patient
(Supplementary Fig. 1a and Supplementary Note 1 for patient
information). One biopsy was taken from a nodule on the scalp
on the posterior region of the head and the other from the back of
the left ear, both with matching non-nodular adjacent tissue
samples. Non-nodular tissues showed normal skin architecture,
with a regular epithelial layer, and a connective tissue of the
dermis composed of a thick ﬁbrillar ECM with embedded vessels
(Fig. 1a). Nodules contained very few, spindle-shaped cells
embedded in an abundant amorphous, pale eosinophilic ECM
(Fig. 1a) as reported for other patients16,17. Sirius red (SR)
staining conﬁrmed differences in ECM between normal and
nodular tissues (Supplementary Fig. 1b). Finally, ultrastructure
analysis by electron microscopy (EM) showed that whereas in the
non-nodular tissue, cells were surrounded by a ﬁbrillar ECM, the
few cells observable in the nodule, were surrounded by a granular
somewhat amorphous matrix with occasional ﬁbrillar bundles
(Fig. 1b).
SDS–PAGE analysis of protein extracts from these tissues
revealed the presence of a single major 100 kDa band in nodular,
but not in non-nodular, samples (Fig. 1c). Mass spectrometry
(MS) analysis showed that it was composed of fragments of the
three alpha chains of collagen VI (Fig. 1c)18. Further analysis
showed that collagen a3 (VI) peptides were also present in higher
and lower molecular weight bands of the gel, showing a,
respectively, wider and narrower peptide coverage, suggesting
partial processing of collagen VI in the tissue or in the biopsy
(Supplementary Fig. 2). Unbiased MS analysis of the total protein
contents of the nodules showed that collagen VI accounted for
more than 30% of the total peptides (Supplementary Fig. 1c) and
that it was the only collagen for which the total peptide count
increased between the nodular and the non-nodular tissues
(Fig. 1d; data available on the PRIDE repository with the
identiﬁer PXD006268 and 10.6019/PXD006268). The MS analysis
also indicated that while non-nodular tissues were enriched in
cellular proteins, the nodules contained signiﬁcant amounts of
serum proteins (Supplementary Table 1), consistent with the
blood vessels leakage proposed in HFS patients19. Drastic
accumulation of collagen VI in nodules was conﬁrmed by
western blot analysis, which also showed moderate increase in
collagen I and ﬁbronectin (Fig. 1e).
To assess whether collagen VI accumulation was due to
increased gene expression, we performed a qRT–PCR analysis on
a panel of ﬁbroblasts derived from different HFS patients
(Supplementary Table 2). The mRNA levels for the a1, 2 and 3
chains of collagen VI (Fig. 1f) and a1 and 2 of collagen I
(Supplementary Fig. 1d) were similar between control and HFS
patient ﬁbroblasts. Differences were observed in the mRNA levels
for the a1 and 2 chains of collagen IV, but with no correlation to
disease (Supplementary Fig. 1e). Thus, loss-of-function mutations
in CMG2 do not lead to constitutive increase in collagen I, IV or
VI gene expression.
Collagen VI accumulation in the uteri of Antxr2 / mice.
Fibrosis has also been reported for the uterus of Antxr2 /
mice10,11. To analyse the potential similarities between patient
nodules and ﬁbrotic mouse uteri, we generated Antxr2 / mice
(Supplementary Fig. 3a–c). In full agreement with the previous
reports10,11, our Antxr2 / female mice displayed a progressive
ﬁbrosis of the uterus (observed in all n¼ 19 mice analysed).
Haematoxylin–eosin (H&E) staining of uterus transverse sections
showed a loss of tissue organization, with disruption of both
myometrial layers and thickening of the endometrium, starting
as early as 6 weeks after birth and becoming increasingly
pronounced, as shown at 38 weeks (Fig. 2a). Staining with
SR conﬁrmed collagen accumulation in the disorganized
uterine layers (Fig. 2a), reminiscent of HFS patient nodules.
Ultrastructure EM analysis conﬁrmed that the myometrium of
Antxr2 / mouse uteri was mostly composed of ECM, in
comparison to that of Antxr2þ /þ mice, which was highly cellular
(Fig. 2b, upper panels). In addition to being drastically more
abundant, the ECM in the uteri of Antxr2 / mouse was
altered in its structure, containing microstructures reminiscent of
collagen VI beaded ﬁlaments, while the ECM of wild-type (WT)
mice uteri was composed of ﬁbrillar structures (Fig. 2b, lower
panel). We next performed immunogold labelling for collagen VI.
Staining was speciﬁc and exclusively extracellular, in the uteri of
both WT and Antxr2 / mice (Fig. 2c and Supplementary
Fig. 4). Interestingly, collagen VI labelling in WT mice uteri was
observed on collagen ﬁbres, while in Antxr2 / mice uteri,
collagen VI labelling was mostly conﬁned to abundant
non-ﬁbrillar structures (Fig. 2c, lower panels). The abundance
of collagen VI-containing ECM in Antxr2 / mice uteri
(Fig. 2c) suggests that the overall content of this collagen, at the
tissue level, must be greatly increased when compared to the uteri
of WT mice.
We therefore analysed protein extracts from mouse uteri by
western blot using a polyclonal antibody (Supplementary Fig. 5a).
Consistent with the EM analysis, a strong increase, with different
relative variation between mice, was observed for all collagen VI
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15861
2 NATURE COMMUNICATIONS | 8:15861 | DOI: 10.1038/ncomms15861 | www.nature.com/naturecommunications
chains, including the alternative a4, a5 and a6 (VI) (Fig. 3a). In
contrast, there was no signiﬁcant change in collagens I and IV
(Supplementary Fig. 5b).
Since ﬁbrosis often involves the transforming growth factor
beta (TGFb) pathway20,21, we probed for its activation by
measuring the mRNA levels of genes regulated by this pathway.
We observed a 1.7-fold increase in TGFb1 mRNA, as well as a
twofold change of in the tumour necrosis factor transcript in the
uteri of Antxr2 / mice compared to control mice (Fig. 3b).
There was, however, no concomitant increase in transcript levels
of TGFb-target genes such as the metalloproteases MMP14, 2, 8
and 9, alpha smooth muscle actin, Col3a1 or lysyl oxidase (LOX)
(Fig. 3b). Thus, the accumulation of collagen VI does not appear
to be a consequence of the activation of the TGFb pathway.
We next analysed the mRNA levels of various collagen genes.
qRT–PCR analysis of WT and Antxr2 / mouse uteri showed
that the mRNA expression of none of the alpha chains of collagen
VI changed in response to Antxr2 knockout (Fig. 3c). The
transcripts for the a1 and a2 chains of collagens I and IV also
remained unchanged (Fig. 3d). Thus, the accumulation of
collagen VI in the uteri of Antxr2 / mice cannot be explained
by transcriptional changes of ECM components or in the TGFb
pathway.
CMG2 and the activity of extracellular metalloproteinases. The
accumulation of collagen VI in patient nodules and mouse uteri
on loss of CMG2 function, without concomitant increases in
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Figure 1 | HFS patient nodules display ECM accumulation and loss of skin adnexa and dermal vessels. (a) H&E staining of formalin-ﬁxed non-nodular
skin and nodule from the ear and the head of a HFS patient. The nodule displays a striking accumulation of ECM, causing secondary loss of skin adnexa,
vascular structures and rarefaction of the dermal cellular component. One biopsy was obtained by tissue. A representative image is shown for each. Scale
bar, 200 mm. (b) Ultrastructure by EM of non-nodular and nodular tissues of a HFS patient. Representative images of non-nodular or nodule tissues at
low magniﬁcation (upper panel) and higher magniﬁcation (lower panel) are shown. At least two grid per tissue biopsies were prepared. Scale bar, 1 mm.
(c,e) Comparison of non-nodular (Nn) and nodule (Nod) tissues from the ear and the head of a HFS patient. Tissue lysates were analysed by SDS–PAGE
using 4–12% Bis-Tris gradient gels under reducing condition followed either by staining with Coomassie blue (c) or by western blot for collagen VI, collagen
I or ﬁbronectin (e). The prominent 100 kDa band (arrowhead) was excised, trypsin digested and its composition analysed by nano LC-MS/MS. Only the
three collagen VI alpha chains were detected with 42 peptides. Migration of the molecular weight markers (in kDa) is indicated on the left. See
Supplementary Fig. 7a for the uncropped version of the western blots. (d) Comparison of the complete tissue lysates from head and ear non-nodular
and nodule analysed by nano LC-MS. The total number of peptides associated with each collagen protein is indicated. Each lysate was run twice in the
nano-LC-MS to account for technical variability and both peptide counts are indicated. (f) Quantitative RT–PCR analysis of mRNAs coding for the a1, a2 and
a3 chains of collagen VI in ﬁbroblast cultures from unaffected control and four HFS patients (P1–P4) (error bars represent s.e.m.; n¼ 3).
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mRNA, indicates that its degradation, rather than its synthesis,
must be defective. We therefore monitored the activity of
extracellular metalloproteases (MMP) in patient nodules and
ﬁbroblasts, in mouse uteri and in tissue cultured cells. In the
nodule biopsies, MMP14, a membrane-bound MMP known to
activate the collagenase MMP2 (ref. 22), was mainly found in
its inactive pro-form. Consistently, MMP2 was also inactive
(Fig. 4a). This inactivation does not appear to be a direct
consequence of CMG2 loss of function since MMP2 activity,
analysed by gelatin zymography, was similar for ﬁbroblasts
derived from HFS and control patients (Fig. 4b).
We next performed a similar analysis on mouse uteri. In
contrast to what was observed for the patient nodules, the
activities of both MMP14 and MMP2 were higher in the uterus of
Antxr2 / mice than in that of control mice (Fig. 4c,d). To
address the issue in a more controlled system, we analysed the
effect of CMG2 silencing on MMP2 activity in tissue culture cells.
CMG2 knockdown in RPE1 cells led to a signiﬁcant increase in
the MMP14 protein level accompanied by a twofold increase in
MMP2 gelatinase activity (Fig. 4e,f).
Altogether, these observations indicate that there is no direct
correlation between the function of CMG2 and the MMP14–
MMP2 activities in affected tissues and thus that collagen VI
accumulation is unlikely to be caused by reduced degradation by
extracellular metalloproteases. Consistently, while the a3 (VI)
chain alone, which is retained intracellular, is sensitive to
degradation by MMP2 in vitro23, full collagen VI ﬁbrils were
reported to be insensitive to MMPs degradation24.
Collagen VI drives uterine ﬁbrosis in Antxr2 / mice.
To again further insight into the functional link between CMG2/
ANTXR2 and collagen VI, we generated Antxr2 / ::Col6a1 /
double knockout mice. In agreement with previous reports,
our Antxr2 / female mice were infertile, due to a parturition
defect10. This can be explained by the perturbation of the uterus
architecture (Fig. 2) and loss of contractile myometrial elements,
which are known to cause drastic changes in the mechanical
properties of the uterus25. In contrast, Col6a1 / females
are fully fertile26. The double knockout mice were viable
with no obvious morphological defects. Quite remarkably,
Antxr2 / ::Col6a1 / females were fully fertile, with 100%
(6/6) of the mice being able to give birth, as opposed to 0%
(described in two studies10,11 and conﬁrmed here for two females)
for Antxr2/ ::Col6a1þ /þ mice. Antxr2 / ::Col6a1 / females
were even able to undergo multiple pregnancies with normal litter
size. Consistently, H&E and SR staining showed that the uteri of
15-week-old Antxr2 / ::Col6a1 / mice in metestrus had a
normal structure of muscle and endometrial layers, with no
detectable accumulation of ECM (Fig. 5 and Supplementary
Fig. 5c). The absence of collagen VI (Supplementary Fig. 5d) was
not accompanied by increase in collagen IV and ﬁbronectin
(Supplementary Fig. 5e). Thus, genetic ablation of collagen VI in
Antxr2 / mice was sufﬁcient to rescue the uterine phenotype.
This striking recovery of the fertility indicates that the defect in
uterus function is secondary to the accumulation of collagen VI,
which caused disruption of the myometrial layers.
CMG2 mediates collagen VI uptake and targeting to lysosomes.
The ability of the Col6a1 knockout to restore tissue function in
the Antxr2 / mouse uterus points to a direct connection
between CMG2 and collagen VI. Since CMG2 loss of function
does not lead to an increase in collagen VI gene expression either
in HFS patient ﬁbroblasts or Antxr2 / mice uteri, we investi-
gated whether CMG2 can physically interact with this ECM
protein. We ﬁrst tested in vitro binding of the CMG2 vWA
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Figure 2 | Structural changes in the uteri of Antxr2 /mice. (a) H&E
and SR staining of formalin-ﬁxed uterine tissues from 38-week-old WT
(Antxr2þ /þ ) and Antxr2 knockout (Antxr2 / ) mice. Antxr2
knockout mice display ECM accumulation with disarray, disruption and
loss of the longitudinal and circular myometrial layers of the uterus.
Representative image of at least n¼ 7 mice per genotype. Scale bar,
200mm. (b) Ultrastructure of Antxr2þ /þ and Antxr2 / uterine
myometrial layer analysed by transmission electron microscopy
(TEM). N¼ 2 mice. Scale bar, 5mm (upper panels) and 500nm
(lower panels). (c) Collagen VI immunogold labelling on the Antxr2þ /þ
and Antxr2 / uterine myometrial layer analysed by TEM. N¼ 2 mice.
Scale bar, 500nm.
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domain with collagen VI. Missense mutations in the metal ion-
dependent-binding domain (MIDAS) of the CMG2 vWA domain
have indeed been found to trigger the most severe form of HFS,
with death in early childhood1,4. We produced recombinant
glutathione S-transferase (GST)-tagged CMG2 vWA domains,
either WT or carrying the MIDAS disrupting D50A mutation27
and probed their binding to a panel of commercially available
puriﬁed ECM proteins by ELISA. At a difference from a previous
study reporting that the CMG2 vWA domain binds collagen IV
and laminin5, we found that the CMG2 vWA domain
preferentially binds collagen VI, in a MIDAS-dependent
manner (Fig. 6a). The discrepancy between the two ﬁndings
might be due to the difference in readout of the ELISA assays and
the fact that ECM proteins were coated onto the ELISA plates
in our approach, as opposed to the vWA domain in the
previous study.
We next investigated whether full-length CMG2 was able to
bind collagen VI in a cellular context and whether this elicits
signal transduction. We have previously shown that when the
anthrax toxin protective antigen (PA) binds to CMG2, src-like
kinases are activated and phosphorylate CMG2, triggering
its endocytosis6. To test whether collagen VI could elicit a
similar response, HeLa cells transiently expressing WT or D50A
CMG2 were plated onto dishes coated with different ECM
proteins and CMG2 tyrosine phosphorylation was monitored.
Phosphorylation of WT CMG2, but not of D50A, was observed
on plating cells on collagen VI or on anthrax PA, whereas no
signiﬁcant CMG2 phosphorylation occurred when cells were
plated on collagen I, collagen IV, laminin or ﬁbronectin (Fig. 6b).
We next tested whether subsequent events involved in PA
internalization were also triggered on collagen VI binding.
b-arrestin is an adaptor protein required for the anthrax
toxin-induced ubiquitination and endocytosis of CMG2
(ref. 28). As previously, cells were plated onto dishes coated
with speciﬁc ECM proteins, b-arrestin was immunoprecipitated
and we probed for the pulldown of CMG2. An interaction was
only observed for cells plated on PA or collagen VI-coated dishes
(Fig. 6c). Thus, CMG2 is able to bind collagen VI, and more
speciﬁcally its triple helical domain, which is the domain present
in the commercially available puriﬁed collagen VI obtained by
pepsinization of human tissues. This binding event leads to
intracellular signals such as the src-dependent phosphorylation of
CMG2 cytoplasmic tail and the recruitment of b-arrestin.
The extracellular accumulation of collagen VI in human and
mouse tissues on CMG2 loss of function, combined with the
knowledge that anthrax toxin-induced CMG2 src phosphoryla-
tion and b-arrestin recruitment lead to endocytosis and transport
to the late endocytic pathway, led us to test whether CMG2
can mediate collagen VI endocytosis and degradation. Puriﬁed
collagen VI tetramers were added to RPE1 cells in which CMG2
expression was silenced or not by stable expression of an
anti-CMG2 shRNA vector. We observed that the collagen VI
complex associated with control cells and underwent degradation
as a function of time, only 20% remaining after 6 h (Fig. 6d). This
degradation could be inhibited by treating cells with the vATPase
inhibitor baﬁlomycin A, indicating that collagen VI undergoes
degradation in lysosomes (Fig. 6d and Supplementary Fig. 6a).
Strikingly, while the collagen VI complex associated with shRNA
CMG2 knockdown RPE1 cells, there was no sign of degradation
even after 6 h (Fig. 6d). Thus, CMG2 is required for the
intracellular degradation of collagen VI.
This was further conﬁrmed using primary human ﬁbroblasts
from patient P3, who carried a frameshift mutation in exon 9,
leading to a premature stop codon and non-sense-mediated
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Figure 3 | Severe collagen VI accumulation in the uteri of Antxr2 /mice. (a) Uterus lysates (20mg) from littermate WT and Antxr2 knockout (KO)
mice were analysed by SDS–PAGE using 4–12% Bis-Tris gradient gels under reducing condition and western blotting against all the collagen VI alpha chains.
The signals obtained varied beyond the dynamic range allowed with western blotting and thus the amplitude of the increase was not evaluated for the
various alpha chains. Coomassie staining was used as loading controls. Migration of the molecular weight markers (in kDa) is indicated on the left.
N¼4 mice. See Supplementary Fig. 7b for the uncropped version of the western blots. (b) Quantitative RT–PCR analysis of genes involved in the TGFb
pathway was performed on uteri from WT (Antxr2þ /þ ) and Antxr2 knockout (Antxr2 / ) mice. (Error bars represent s.e.m.; n¼ 3; *Po0.05; two-tailed
unpaired t-test). (c,d) Quantitative RT–PCR analysis of mRNAs coding for the a1 and a2 chains of collagens I, IV and VI in WT (WT) and Antxr2 KO
(KO) mouse uterus. (Error bars represent s.e.m.; n¼6–7; N.S., P40.05; two-tailed unpaired t-test).
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mRNA degradation (Supplementary Fig. 6b). As observed for
RPE1 cells, the collagen VI complex associated with control
patient cells and underwent degradation as a function of time,
with only 35% of the initial level detectable after 6 h (Fig. 6e).
Strikingly, P3 ﬁbroblasts were unable to degrade collagen VI, even
if the complex was found associated with cells. Thus, HFS patient
ﬁbroblasts essentially devoid of CMG2 protein are unable to
degrade collagen VI. Loss of CMG2 does not have a pleiotropic
effect on the endocytic pathway since internalization and
lysosomal degradation of mouse IgGs was unaffected by CMG2
knockdown (Supplementary Fig. 6c).
Altogether, these observations show that CMG2 is a bona ﬁde
collagen VI receptor, which has the capacity to target its ligand
for degradation. So far, no speciﬁc receptor for collagen VI has
been identiﬁed. Collagen VI can bind several integrins, such a1,
a2, a5, a10 and a11, as well as to the cell surface proteoglycan
CSPG4/NG2 (ref. 29), but not as an exclusive ligand. As these
proteins, CMG2 binds to the triple helical domain of collagen VI
(Fig. 6a). This differs from its related protein ANTXR1/TEM8,
which was reported to bind the C5 domain of collagen VI,
a domain that is cleaved during collagen VI maturation30.
Discussion
Analyses of HFS patient nodules and of Antxr2 / mouse uteri
pointed towards a non-genetic interaction of CMG2 with collagen
VI. Studies on puriﬁed proteins and tissue culture cells revealed
that collagen VI can bind to the vWA domain of CMG2 via
its triple helical domain. While a complete characterization of
CMG2 interaction with collagen VI, including the speciﬁc-
binding site and afﬁnity, requires further studies, we found that
this interaction leads to ligand-induced endocytosis of the
receptor, which targets collagen VI to lysosomal degradation.
These ﬁndings are consistent with previous observations showing
that collagen VI ﬁbrils are insensitive to MMPs24 but require
serine and cysteine hydrolases, such as those found in lysosomes,
for degradation31.
These ﬁndings provide an explanation for the collagen VI
accumulation observed in certain tissues or body parts of HFS
patients, leading to progressive loss of tissue integrity and thereby
function. Why certain tissues are particularly sensitive to loss of
CMG2 function requires further investigation. The sensitivity of
the mouse uterus might be due to the ﬂuctuating level of collagen
VI in this organ, in particular during early gestation32.
While excess of collagen VI is detrimental, decreased levels also
lead to diseases, such as Ullrich congenital muscular dystrophy
and Bethlem myopathy (OMIM #25090, #158810)33,34. Thus,
the amount of collagen VI in the extracellular environment needs
to be tightly controlled, and CMG2 appears to play a critical role
in this process.
Binding of collagen VI to CMG2 might not systematically
lead to endocytosis and degradation. An equilibrium between
binding/signalling and endocytosis must exist, which depends on
the concentration of collagen VI in the cellular environment,
as described for the EGF receptor35. Also, the massive
accumulation of collagen VI in the extracellular environment
might not be entirely due to the absence of endocytosis. Since
collagen VI was found to modulate MMPs activity10,36,
its accumulation could sequester inactive MMPs creating a
positive feedback loop of ECM accumulation, leading to ﬁbrosis37.
The data obtained in Antxr2 / ::Col6a1 / mice indicates
that collagen VI is the key initiator of the uterus ﬁbrosis and
most likely of nodule formation in humans. While inhibition of
collagen synthesis has so far not been evaluated as a strategy to
treat ﬁbrotic disease38, speciﬁc targeting of collagen VI could be a
new therapeutic strategy for HFS patients to attenuate or even
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Figure 4 | Regulation of MMPs activity on CMG2 loss of function.
(a) Lysates from non-nodular (Nn) and nodule (Nod) tissues from the ear
and the head were analysed by SDS–PAGE and western blotting against
MMP2 and MMP14. (b) Supernatant of HFS patients or control ﬁbroblasts
were normalized to protein concentration and analysed by gelatin
zymography. Cell lysates were analysed by SDS–PAGE and western blotting
against MT1–MMP, CMG2 and actin as loading control. (c) Uterus lysates
from Antxr2þ /þ or Antxr2 / mice were analysed by SDS–PAGE and
western blotting against MMP2 and MMP14. (d) Quantiﬁcation of active
MMP2 and MMP14 by densitometric analysis. (e) RPE1 cells were treated
with control siRNA or siRNA against CMG2 for 72 h. Cell supernatant were
then normalized to protein concentration and used for enzyme zymography.
Cell lysates were analysed by SDS–PAGE and western blotting against
CMG2, MMP14 and actin as a loading control. (f) Quantiﬁcation of active
MMP2 and MMP14 by densitometric analysis. (d,f) Error bars represent
s.e.m.; n¼ 3; *Po0.05; **Po0.01; two-tailed unpaired t-test compared to
control. See Supplementary Fig. 8a–d for the uncropped version of the
western blots.
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revert the formation of nodules. As a novel collagen VI regulator,
it will also be of great interest to investigate the role of CMG2 in
the collagen VI-dependent regulatory processes such as muscle
homoeostasis14 and adipogenesis12.
Methods
Human samples. Human tissues, for analyses or derivation of ﬁbroblasts, were
obtained after patient surgery, with explicit written consent of the patients and/or
their legal tutors. Fibroblasts derived from HFS patients were included in a
biobank dedicated to HFS and afﬁliated to the Lausanne University Hospital
biobank. Our study followed the tenets of the declaration on Helsinki and
was approved by the ethical committee of the Lausanne University Hospital
(authorization A070055).
Generation of Antxr2 / and Antxr2 / ::Col6a1 / mice. CMG2
knockout mice were generated by the Mouse Clinical Institute (Strasbourg, France)
following a routine protocol. Mouse ES cells (MSI-129Sv/Pas) were electroporated
with a 13 kb targeting vector with 50 and 30 homology arms targeting Antxr2 exon
3. A neoR cassette was used for G418 selection of positive clones, and a ﬁrst PCR
screen on the loxP site and the 30 homology arm was performed. Homologous
recombination was determined by Southern blotting with neoR and Antxr2 30
probes. ES cell clones were then injected into blastocysts and implanted into
pseudopregnant mice. Breeding of chimeric mice to achieve germ-line transmission
was performed. The neoR cassette was removed by ﬂippase-mediated deletion
(FLP). Heterozygous (Antxr2þ / ) mice were generated by Cre-mediated recom-
bination following breeding with Nestin-Cre mice. The mice were backcrossed for
10 generations onto the C57Bl6/J genetic background (Charles River Laboratories).
Antxr2þ /þ mice were kept in a speciﬁc pathogen free (SPF) environment with
12 h light and 12 h dark cycle.
Col6a1 / mice were generated by targeted deletion of the gene exon 2
(ref. 26). Col6a1 mutant mice were generated in the C56Bl6/N background and
backcrossed with WT animal at least 10 times. Antxr2::Col6a1 double-mutant mice
were generated by crossing heterozygous animals. Antxr2::Col6a1 were housed in a
conventional facility on a 12 h light/dark cycle. Antxr2::Col6a1 double-mutant mice
were always used at the F1 generation and were a mix of the C56Bl7/J and N
substrains. Experiments were all performed using littermate from the different
genotypes.
Depending on the experiment, female mice were used from 15 weeks up to
38 weeks.
For animal experimentation, all procedures were performed according to
protocols approved by the Veterinary Authorities of the Canton Vaud and
according to the Swiss Law (licence VD 2144.4, EPFL).
Genotyping. Mice were genotyped by PCR ampliﬁcation using genomic DNA
extracted from the tail. Several set of primers depending on the gene to test were
used: for the Antrx2 knockout alleles, forward primer 50-GGTGACTTTTGTCT
GGACTCTTATC-30 and reverse primer 50-CAGATACGTGGATGGTTGC-30 .
For the genotyping of the Col6a1 knockout alleles, the forward primer 50-CTGCTG
GTGAGAATGGATGGTGT-30 and reverse primer 50-TGTGCCGAGTCATAG
CCGAATAG-30 were used.
Histology. Mouse tissues were ﬁxed in 4% paraformaldehyde overnight at 4 C
and embedded in parafﬁn. Serial sections (4mm) were stained with H&E and SR.
The slides were then analysed in a blinded fashion by a board-certiﬁed veterinary
pathologist.
Mouse uteri were analysed during the metestrous phase. Indeed, uterine tissues
change during the menstruous cycle and can potentially mimic cellularity
rarefaction and ECM expansion, such as oedema. Such changes are however
minimal during the metestrous phase.
EM. Mice were perfused via the heart with a buffered mix of 2.5% glutaraldehyde
and 2% paraformaldehyde in phosphate buffer (0.1M, pH 7.4). The animal was left
for 2 h and then 100 mm thick sections cut in the transverse plane through the
middle portion of the uterus using a vibratome. These slices were then postﬁxed
with 1.5% potassium ferrocyanide and 1% osmium tetroxide, then with 1%
osmium tetroxide alone, and ﬁnally in 1% aqueous uranyl acetate. They were
dehydrated with increasing concentrations of alcohol, embedded in Durcupan resin
and hardened at 65 for 24 h. A segment of the uterine wall was then thin sectioned
using a diamond knife at a thickness of 50 nm and mounted onto single slot copper
grids with a pioloform support ﬁlm, stained with lead citrate and uranyl acetate,
and imaged at 80 kV in a TEM (Tecnai Spirit, FEI Company).
Cryo-immuno EM. To localize collagen VI within the different compartments of
the uterine wall, we used cryo-immuno EM. Mice were perfused via the heart with
a buffered solution of 4% paraformaldehyde and the uterus was then removed and
sliced transversally with a razor blade. These sections were then inﬁltrated with a
2.3M solution of sucrose, and frozen in liquid nitrogen onto aluminium mounting
pins and stored. Cryo sections were cut at  90 C with a diamond knife at 90 nm
thickness and collected onto formvar support ﬁlms on copper grids, these were
then brought to room temperature ready for immuno-staining. The grids were
incubated overnight with primary antibody, washed and then exposed for 3 h to a
secondary antibody carrying 10 nm gold particles. After washing, and ﬁxation with
buffered glutaraldehyde, the grids were next stained with uranyl acetate, followed
by uranyl acetate in methylcellulose on ice, and then air dried ready for imaging
with transmission EM.
Antibodies and reagents. Rabbit anti-collagen I antibody was purchased from
Rockland antibodies (#600-401-103-0.5) and used at 1:2,000. Rabbit anti-collagen
IV (ab6586) and collagen VI (ab6588) antibodies were from Abcam and used at
1:3,000 dilution. The antibodies against the alpha chains of mouse collagen VI were
a kind gift of Raimund Wagener39 and used at 1:500. Rabbit anti-ﬁbronectin
antibody was from Sigma (F3648) and used at 1:1,000 dilution. Rabbit anti-MMP2
antibody was from Abcam (ab37150) and used at 1:2,000 dilution. Mouse
anti-MMP14 antibody was from Millipore (MAB3328) and used at 1:3,000
dilution. Rabbit b-arrestin 1 antibody was from Thermo Fischer Scientiﬁc
(PA5-19582) and used at a 1:1,000 dilution. Mouse anti-actin antibody was
H
&E
100 μm
100 μm 100 μm 100 μm 100 μm
100 μm 100 μm 100 μm
Si
riu
s 
re
d
Antxr2 +/+ Col6a1 +/+ Antxr2 +/+ Col6a1–/– Antxr2 –/– Col6a1 +/+ Antxr2 –/– Col6a1 –/–
15w; metestrus
Figure 5 | Deletion of Col6a1 is sufﬁcient to rescue the uterine phenotype of Antxr2 /mice. H&E and SR staining of uterine tissues from 15-week-old
Antxr2þ /þ ::Col6a1þ /þ , Antxr2þ /þ ::Col6a1 / , Antxr2 / ::Col6a1þ /þ and Antxr2 / ::Col6a1 / mice in metestrus. Failure of parturition in
Antxr2 / ::Col6a1þ /þ mice is caused by the same mechanisms described for Antxr2 / (ref. 10), and this phenotype is reversed after ablation of
collagen VI in Antxr2 / ::Col6a1 / mice. Representative image of at least n¼ 3 mice per genotype. Scale bar, 100mm.
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from Millipore (MAB1501) and used at a 1:3,000 dilution. Anti-phospho-Tyr
(clone 4G10) was from Upstate and used at 1:500. Mouse anti-V5 antibody
were purchased from Invitrogen and used at a 1:2,000 dilution and rabbit anti-V5
antibody from Covance and used at a 1:3,000 dilution. Anti-mouse or human
CMG2/ANTXR2 are monoclonal antibodies developed by rat genetic
immunization and puriﬁed from hybridomas supernatant (Genovac) both used at
1:2 dilution. Horseradish peroxidase-conjugated secondary antibodies were from
Pierce and used at 1:2,000 dilution. Protein G beads were purchased from GE
Healthcare.
Patient tissue preparation and MS analysis. HFS patient tissue samples of
similar weight were cut with a scalpel in 200ml of lysis buffer (2% SDS in Tris-HCl
100mM). After processing into very small pieces, another 200 ml of lysis buffer
were added. The suspended tissues were then put in a Lysing Matrix tube (MP
Biomedicals) and homogenized in a tissue lyser (Qiagen) 3 for 5min, with 2min
resting period at 4 C between each round. Homogenates were then pelleted at
5,000 r.p.m. for 3min at 4 C. Protein amount was quantiﬁed by BCA assay
(Pierce). After protein concentration normalization, DTT was added to achieve a
ﬁnal concentration of 50mM. Protein concentrations of homogenates were
determined by BCA (Pierce) and equal amount of proteins were analysed by
SDS–PAGE using 4–12% Bis-Tris gradient gels under reducing condition followed
by Coomassie staining or western blotting, or 20 mg in 20 ml (ﬁnal concentration
1 mg ml 1) of the homogenates were analysed by nano LC-MS/MS. Each sample
was digested by ﬁlter-aided sample preparation40. Peptides were desalted on C18
StageTips41 and dried down by vacuum centrifugation before mass spectromic
analysis. For LC-MS/MS analysis, peptides were resuspended and separated by
reversed-phase chromatography on a Dionex Ultimate 3000 RSLC nanoUPLC
system in-line connected with an Orbitrap Q Exactive Mass-Spectrometer (Thermo
Fischer Scientiﬁc). Each homogenate was analysed twice (2 10ml) to assess
technical reproducibility. For protein identiﬁcation from Coomassie staining, the
relevant protein band was excised and trypsin digested before identiﬁcation with
nano LC-MS/MS.
MS data analysis. Database search was performed using Mascot, MS-Amanda
and SEQUEST in Proteome Discoverer v.1.4 against a UniProt human database
release 2014_06. All searches were performed with trypsin cleavage speciﬁcity,
up to two missed cleavages allowed and ion mass tolerance of 10 p.p.m. for the
precursor and 0.05Da for the fragments. Carbamidomethylation was set as a
ﬁxed modiﬁcation, whereas oxidation (M), acetylation (Protein N-term),
phosphorylation (STY) were considered as variable modiﬁcations. Data were
further processed and inspected in the Scaffold 4 software (Proteome Software).
55
55
55
55
Co
llag
en
 I
Co
llag
en
 IV
Co
llag
en
 VI
An
thr
ax
 PA
La
mi
nin
Fib
ron
ec
tin
Un
co
ate
d
55
55
55
45
– 1 h 3 h 6 h – 1 h 3 h 6 h
RPE1 WT RPE1 shCMG2 Ctrl P3
– 1 h 3 h 6 h – 1 h 3 h 6 h
Collagen VI Collagen VI
CMG2
Actin Actin
CMG255
45
CMG2
Beta-
arrestin
IP V5
CMG2
WT
CMG2
D50A
pTyr
pTyr
a b
c d e
IP beta-arrestin
–Bafilomycin
210
0.25
300
100
0
200
*
**
GST
WT
D50A
***
*
**
0.20
0.15
0.10
Ab
so
rb
an
ce
 @
 4
50
 n
m
%
 o
f C
M
G
2 
Co
lP
Co
lla
ge
n 
VI
 le
ve
l
(%
 of
 1 
h)
Co
lla
ge
n 
VI
 le
ve
l
(%
 of
 1 
h)
CM
G
2 
pT
yr
(%
 of
 av
e
ra
ge
 s
ig
na
l)
0.05
0.00
400
200 +CMG2 –Baf Ctrl
P3
+CMG2 +Baf
–CMG2 –Baf150
100
50
0
150
100
50
0
1 2 3 4 5 6 7
**
***
*
Time (h)
1 2 3 4 5 6 7
Time (h)
300
200
100
0
Substrate
Co
llag
en
 I
Co
llag
en
 IV
Co
llag
en
 VI
La
mi
nin
Fib
ron
ec
tin BS
A
Co
llag
en
 I
Co
llag
en
 IV
Co
llag
en
 VI
La
mi
nin
Fib
ron
ec
tin
An
thr
ax
 PA
Un
co
ate
d
Co
llag
en
 I
Co
llag
en
 IV
Co
llag
en
 VI
La
mi
nin
Fib
ron
ec
tin
An
thr
ax
 PA
Un
co
ate
d
Figure 6 | Collagen VI binding to CMG2 leads to signalling and degradation. (a) Collagen I, collagen IV and collagen VI, ﬁbronectin, laminin, PA and BSA
were coated on 96-well plates. Subsequently, puriﬁed GST, WT CMG2 vWA-GST (WT) or D50A mutant CMG2 vWA-GST (D50A) were incubated at
1mg ml 1 for 2 h at 25 C and the interaction revealed using an antibody against GST and a horseradish peroxidase-coupled secondary antibody. The
reaction was quantiﬁed with a plate reader at 450 nm. (b) HeLa cells were transfected for 48 h with a C terminally V5-tagged WTor D50A mutant CMG2
(D50A), and subsequently plated onto different dishes coated or not with either collagen I, collagen IV, collagen VI, PA, laminin or ﬁbronectin. Cells were
collected 60min after plating. V5 immunoprecipitates were then analysed by SDS–PAGE using 4–12% Bis-Tris gradient gels under reducing condition and
western blotting for phospho-Tyr and V5. The phospho-Tyr signal after immunoprecipitation against the V5-tag was quantiﬁed by densitometric analysis,
and the values normalized as a percentage of the average signal. (c) RPE1 cells were plated on dishes coated with collagen I, collagen IV and collagen VI, PA,
laminin, ﬁbronectin or on uncoated dishes. Cells were collected 60min after plating. b-arrestin immunoprecipitates were then analysed by SDS–PAGE using
4–12% Bis-Tris gradient gels under non-reducing condition and western blotting for endogenous CMG2 and b-arrestin. The CMG2 signal was quantiﬁed by
densitometric analysis. (d–e) CMG2 knockdown RPE1 cells (d) or control and P3 ﬁbroblasts (e) were blocked with 5% bovine serum albumin 30min before
addition of puriﬁed collagen VI tetramer at 1 mgml 1. Cells were collected 1, 3 or 6 h later. Collagen VI degradation was assessed by SDS–PAGE using
4–12% Bis-Tris gradient gels under non-reducing condition and western blotting for collagen VI, endogenous CMG2 and actin as a loading control.
(a–e) Error bars represent s.e.m.; n¼ 3; *Po0.05; **Po0.01; ***Po0.001; two-tailed unpaired t-test to BSA (a), uncoated (b,c) or control (d,e).
See Supplementary Fig. 8e–h for the uncropped version of the western blots.
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ELISA assay. WT and D50A CMG2 vWA domains were cloned in pGex-4T-1
plasmid (GE Healthcare) and expressed in E. coli as GST fusion proteins. For
ELISA, 1 mg of collagen I (Corning ref. 354243), collagen IV (Corning ref. 354245),
collagen VI (Corning 354261), laminin (Sigma L6274), ﬁbronectin (Corning
ref. 354008) and BSA in 100ml PBS were coated for 2 h at room temperature on
Maxisorp 96-well plates (NUNC). Samples were treated for 30min with TBST
(TBS pH 7.5 with 0.1% Tween) and then incubated for 2 h at room temperature
with 0.1 mg of recombinant GST-vWA protein in 100 ml of TBST–BSA (TBS pH 7.5
with 0.1% Tween, 1% BSA, 1mM CaCl2, 1mM MgCl2). Samples were then washed
with TBST–BSA and incubated for 1 h with an anti-GST antibody in TBST–BSA.
After a TBST–BSA wash, samples were incubated for 1 h with a secondary antibody
coupled to horseradish peroxidase in TBST–BSA. Levels of bound GST-vWA were
measured by adding 0.4mgml 1 o-phenylene-diamine (Sigma) to the samples and
reading the peroxidase activity at 405 nm on a 96-well plate reader (SpectraMax
M2, Molecular Devices).
Cells and plasmids. HeLa cells (ATCC) were grown in modiﬁed eagle’s medium
(Sigma Life Science) supplemented with 10% fetal calf serum, 2mM L-glutamine,
non-essential amino acids, penicillin and streptomycin (GIBCO).
Primary ﬁbroblasts were isolated after incubating patient biopsies 5min at 37 C
in trypsin, followed by trypsin inactivation in Dulbecco’s modiﬁed eagle medium
(Sigma Life Science) supplemented with 10% fetal calf serum, penicillin and
streptomycin (GIBCO). Dissociating ﬁbroblasts where then ampliﬁed and
subsequently frozen in complete medium with 10% dimethylsulfoxide and kept in
liquid nitrogen. Fibroblasts where used until passage 6. All cell lines were tested for
mycoplasma contamination.
Human CMG2 (isoform 4, Uniprot identiﬁer P58335-4) was cloned in a
pcDNA3.5/V5-HIS-TOPO expression vector.
siRNA and cDNA transfections and phosphorylation assay. CMG2 siRNA was
purchased from Qiagen. As a control siRNA, the following target sequence of the
viral glycoprotein VSV-G: 50-attgaacaaacgaaacaagga-30 was used. Transfection of
100 nM of siRNA were carried out using Interferin (PolyPlus Transfection),
and the cells were analysed at least 72 h after transfection.
HeLa cells were transfected with WT or D50A CMG2 tagged with the V5
epitope using Fugene according to the manufacturer’s protocol (Promega).
After 48 h, conﬂuent cells were detached with PBS–EDTA, counted and equally
distributed on coated dishes. A total amount of 5 mg of collagen I, collagen IV,
collagen VI, laminin, ﬁbronectin and PA were coated on a six-wells plate for 2 h at
room temperature. Cell adhesion was allowed for 60min at 37 C, and the cells
were subsequently washed 3 in PBS 1 at 4 C and lysed for 30min at 4 C in
IP buffer (0.5% NP-40, 500mM Tris-HCl pH 7.4, 20mM EDTA, 10mM NaF,
30mM sodium pyrophosphate decahydrate, 2mM benzamidin, 1mM PMSF,
1mM N-ethyl maleimide), supplemented with a cocktail of proteases inhibitors
(Roche) and phosphatase inhibitors (Sigma). Cell lysates were spun down at
5,000 r.p.m. for 5min and the supernatant were submitted to immunoprecipitation
using 1 ml of mouse anti-V5 antibody and protein G beads overnight at 4 C on a
rotating wheel. Protein G beads were then washed 3 and boiled in Laemmli
buffer under reducing conditions for 5min before analysis by SDS–PAGE using
4–12% Bis-Tris gradient gels under reducing condition and western blotting with
phospho-Tyr antibody and rabbit anti-V5 antibody.
Co-immunoprecipitation. Conﬂuent RPE1 cells were detached with PBS–EDTA,
counted and equally distributed on coated dishes. A total amount of 5 mg of
collagen I, collagen IV, collagen VI, laminin, ﬁbronectin and PA were coated on a
six-wells plate for 2 h at room temperature. Cell adhesion was allowed for 60min at
37 C, and the cells were subsequently washed 3 in PBS 1 at 4 C and lysed for
30min at 4 C in CoIP buffer (PBS 1 , 1% Triton X-100 and protease inhibitor
cocktail (Roche)) for 30min on ice. Lysates were then spin down at 5,000 r.p.m.
on a tabletop centrifuge and the supernatant incubated with protein G beads for 1 h
on a wheel at 4 C. The beads supernatant was then incubated with 3 ml of rabbit
anti-b-arrestin for 3 h on a wheel at 4 C, to be ﬁnally captured on 40ml of protein
G beads for 1 h on a wheel at 4 C. Immunoprecipitates were then washed 3 in
CoIP buffer and samples were boiled in non-reducing Laemmli buffer for 5min
before SDS–PAGE and western blotting against endogenous CMG2.
Endocytosis assay. Control or RPE1 cells stably expressing a small hairpin RNA
targeting CMG2 mRNA were seeded on plates and incubated overnight in DMEM
complemented with Gropro (Zen-Bio), to remove the collagen VI present in FBS.
The next days, cells were incubated or not for 60min with 100 nM baﬁlomycin
(Sigma). Thirty minutes before the addition of puriﬁed collagen VI tetramer (kind
gift from P. Bonaldo), 5% BSA was added to the cell culture medium to block
aspeciﬁc binding. A measure of 1 mgml 1 of puriﬁed collagen VI tetramer was
then added to cells. Cells were lysed in IP buffer (0.5% NP-40, 500mM Tris-HCl
pH 7.4, 20mM EDTA, 10mM NaF, 30mM sodium pyrophosphate decahydrate,
2mM benzamidin, 1mM PMSF, 1mM N-ethyl maleimide, cocktail of proteases
inhibitors (Roche) and phosphatase inhibitors (Sigma)) 1, 3 and 6 h after collagen
VI addition. Protein quantity was measured using BCA assay kit (Pierce) and equal
amount of proteins boiled in Laemmli buffer under non-reducing conditions for
5min before analysis by SDS–PAGE using 4–12% Bis-Tris gradient gels and
western blotting with collagen VI antibody and rat monoclonal anti-CMG2
antibody. Actin was used as a loading control.
Gelatin zymography. Cells were put in serum-free media the night before
the experiment. Cell supernatant (SN) were normalized according to protein
concentration. Non-reducing Laemmli buffer was added to SN and let rest
for 10min at room temperature. Samples were then loaded on a 0.1% gelatin
acrylamide gel and run at 125V. The gel was then incubated 30min at room
temperature in renaturing buffer (2.5% Triton X-100 in double distilled
H2O—ddH20). Renaturing buffer was then replaced by developing buffer for
30min to equilibrate (50mM Tris-HCl pH 8, 5mM CaCl2, 0.2% azide). Fresh
developing buffer was then added and the gel was incubated at 37 C overnight.
The gel was then washed 10min with ddH2O, and put in ﬁxation solution (40%
methanol, 10% acetic acid, ddH2O) for 20min at room temperature. After ﬁxation,
the gel was washed in ddH2O and stained with Coomassie blue for at least 1 h at
room temperature. The gel was ﬁnally destained in ddH2O overnight at 4 C
without shaking and analysed the next day.
RNA extraction and quantitative real-time PCR. Total RNA was extracted from
conﬂuent cell culture using RNA easy mini extraction kit (Qiagen). Mice tissues
were disrupted using Lysing Matrix tube (MP Biomedicals) and homogenized in a
tissue lyser (Qiagen) 3 5min, with 2min resting period at 4 C between each
round, followed by RNA extraction using RNA easy mini extraction kit (Qiagen).
RNA concentration was measured by spectrometry and 500 ng of total RNA was
used for reverse transcription. We then used a 1/5 dilution of the cDNA to perform
quantitative real-time PCR using SYBR green MasterMix (Life Technology) on a
7900HT Real-Time PCR System (Applied Biosystem). mRNA level was normalized
using TATA-binding protein and b-microglobulin for RNA derived from human
cell culture and cytochrome c oxydase and b-actin for RNA derived from mice
tissues. See Supplementary Table 3 for the list of the primers used in this study.
Statistical analysis. Calculations were performed using GraphPad Prism 5.0
(GraphPad Software, Inc.). When two groups were compared, an unpaired
Student’s t-test was used to test signiﬁcance, variance between the groups were of
similar value. Statistical signiﬁcance was reached for P-value o0.05.
Data availability. The MS proteomics data have been deposited to the
ProteomeXchange Consortium via the PRIDE42 partner repository with the
data set identiﬁer PXD006268 and 10.6019/PXD006268.
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